Get documents about "vaccine_brochure
Shared by: huanghengdong
-
Stats
- views:
- 3
- posted:
- 1/18/2012
- language:
- Latin
- pages:
- 4
Document Sample
GTCBIO CONFERENCE
Co-Sponsored by THE SCIENTIST MAGAZINE
SABIN VACCINE INSTITUTE, VAbio and MDbio
Tel: 626-256-6405. Fax: 626-256-6460. http://www.gtcbio.com
Vaccines
- From Political, Socio-Economic, Scientific, Provider, User and Legal Viewpoints
October 22-24, 2003—Hilton Crystal City, Arlington, VA
(Across the Potomac River from Washington, DC)
KEY POINTS OF CONFERENCE
1) High-quality, current reports of scientific progress in vaccine research and development.
2) Update on efforts to create incentives at all stages for the private sector to encourage vaccine development.
3) Defining the role of the public and private sectors, and the policy priority.
4) Establishing better communication about vaccines and vaccinations between the involved parties (scientists,
policy experts, legislators, economists, regulators, funding sources, manufacturers, recipients and attorneys).
5) Vaccine safety and public acceptance: improved vaccines, efficacy evaluations, modifications in "no-fault
childhood victims fund", Tort reform, and innovative funding approaches.
6) Developing vaccines in startup companies.
7) Vaccine funding opportunities.
Keynote Address: Vaccines for Bioterrorism Agents
Lance Gordon, CEO, Vaxgen Corporation
Other Confirmed Speakers and Conference Committee*
Dr. Mathuram Santosham, Director Mr. Chris Collins, Executive Director Mr. Henry A. Waxman, J.D., Congressman
BSPH, Johns Hopkins University AIDS Vaccine Advisory Coalition California 30th Congressional Distr.
Dr. Georges Benjamin Dr. Neal Halsey Dr. George Lowell
Executive Director, APHA Director, Institute of Vaccine Safety CSO, ID Biomedical
Dr. Kreesten Madsen Dr. Carl Alving, Chief, Dept. of Dr. Jay Berzofsky, Chief Mol. Immuno. &
Danish Epidem. Science Center Membrane Biochem., WRAIR Vaccine Lab., National Cancer Instititute
Mr. Paul Clinton Harris, Deputy Asso. Dr. John J. Donnelly *, Senior Director Dr. H.R. Shepherd*, Chairman, Board of
Attorney, Department of Justice Vaccine Department, Chiron Trustees, Sabin Vaccine Institute
Dr. Sharon Mates, Chairman and CEO Mr. Victor Schwartz, JD, Esq, Senior Dr. Daniel Zimmerman*, Senior Vice
Functional Genetics, Inc., and Partner and Chairman, Public Policy President, CEL-SCI, Corporation
Intra-Cellular Therapies, Inc. Practice, Shook, Hardy & Bacon LLP Chairman, Conference Committee
Mr. Barry Nace, JD, Managing Partner Dr. Kenneth S. Rosenthal*, Professor Mr. Paul Sharer, Partner, Intellectual
Paulson and Nace Dept. of Microbiology, NEOUCOM Intellec. Property Group, Pillsbury Winthrop
Mr. Stan Yakatan, Venture Capitalist Dr. Ciro A. de Quadros Dr. Peter Hotez, Prof and Chairman
Chairman, Managing Partner of Director International Programs Dept of Microbiology and Tropical Medicine
Katan Associates International Sabin Vaccine Institute GWU
Dr. Lester Crawford Dr. Stephen L. Hoffman Dr. Richard Gallagher*
Deputy Commissioner, FDA CEO and CSO, Sanaria Editor, "The Scientist"
Mr. James Wood, J.D. Mr. Russell P. (Rip) Wilson Mr. John May, Venture Capitalist
Director Partner of Oakland Office VP, CFO & General Counsel Managing Partner, New Vantage Group
Reed Smith Iomai Corp. Managing General Partner, Calvert Social Fund
Day 1 Wednesday, October 22, 2003 and Compensation and Liability
Representative Henry A. Waxman, U.S
1:00 Registration House of Representatives
3:00 Chairman's Opening Remarks 8:45 Status of Healthcare Legislation Impacting
Daniel Zimmerman, Sr. Vice President R&D, Vaccines
Cel-Sci Corp. Speaker from Senate invited
3:05 Introduction to the Program and Its Objectives 9:15 Vaccines Importances from the Public
Richard Gallagher, Editor, The Scientist Health Perspectives
Georges Benjamin, Executive Director
3:35 Introduction of New Vaccines into Developed and American Public Health Association
Developing Countries, Example of Hib Vaccines
Mathuram Santosham, Professor and Director, 9:45 Coffee Break
School of Public Health, Johns Hopkins University
10:15 Effect of Proposed Tort Legislation on
4:05 Need and Prospect of Vaccines for Malaria, TB Vaccines as Viewed by an Advocate of Tort
and AIDS Reform
Chris Collins, Executive Director, AIDS Vaccine Victor Schwartz, Partner and Chairman,
Advisory Coalition Public Policy Group, Shook Hardy and
Bacon
4:35 Development of a First Generation Recombinant
Anti-Hookworm Vaccine and Its Use for the 10:45 Immunization from Product Liability as a
World's Most Impoverished Critical Component of Antiterrorism
Peter Hotez, Professor and Chairman, Dept of Biologics
Microbiology and Tropical Medicine, GWU James Wood, Director Partner of
Oakland Office, Reed Smith
5:05 The Use and Power of Vaccines to Control and
Eradicate Diseases Such as Small Pox, Polio, and 11:15 Vaccines and Tort Reform Legislation from
Measles Eradication Initiatives ATL View
Ciro de Quadros, Director, Sabin Vaccine Managing Partner, Paulson and Nace
Institute International Programs Former President of American Trial
Lawyers
5:35 Reception and Poster Session on Breaking Events
1. SARS, WNV and Monkeypox 11:45 Lunch
2. Role of Vaccines for Weapon of MAss Destruction
3. Vaccines for WMD as Models for Other Agents 1:30 A Prationer Looks at the Patent Process and
How It Works and Doesn't
7:30 Keynote Address: Vaccines for Bioterrorism Agents Paul Sharer, Intellectual Property/
Lance Gordon, CEO, Vaxgen Corporation Biotechnology Life Sciences
Phillsbury Wintrop
Day 2 Thursday, October 23, 2003
2:00 Update on Patent Reform: Including
8:20 Introduction, Session Chairman Pooling, Extention and Restoration
Daniel Zimmerman, Sr. Vice President R&D, PharMa/Bio Representative, Invited
Cel-Sci Corp.
2:30 A Venture Capitalist View on Vaccine
8:30 Legislative Developments Affecting Vaccines Investment Opportunities
Including: Vaccine Supply; Vaccines to Protect Stan Yakatan, Chairman, Managing
Against Bioterrorist Attacks; Partner, Katan Associates International
3:00 How a Social Venture Fund Considers Vaccines 11:35 Discussion on Vaccine Safety
John May, Managing Partner, New Vantage
Group 12: 05 Lunch
3:30 Coffee Break 1:30 Chairperson's Remarks: Preparing for the
Future
4:00 Funding/Financing and Technology Transfer Kenneth S. Rosenthal, Professor
Opportunities from R&D to Phase II/III Stage Microbiology and Immunology,
from Government and Foundations Northestern Universities, College of
Mr. Russell P. (Rip) Wilson, VP, CFO & General Medicine
Counsel, Iomai Corp
2:00 Refinements in Vaccines by Consideration
4:30 A History of FDA by Looking at What FDA Is and of Types and Requirement of Particular
Is Not and What It Can Do and Can Not Do Immune Responses
Lester Crawford, Deputy Commissioner, FDA, Jay Berzofsky, Chief, Section of
Immunogenetics and Vaccines, National
5:00 Roundtable on Improving Financing Opportunities Cancer Institute
for Vaccines
Paul Harris, Moderator, Deputy Associate 2:30 Improved Delivery of Vaccines by Modern
Attorney General, DOJ Improved Adjuvants
Carl Alving, Chief, Dept. of Membrane
Day 3 Friday, October 24, 2003 BioChemistry, WRAIR
8:30 Introduction, Conference Chairman 3:00 Next Generation of Vaccines
Stephen L Hoffman, CEO, CSO, Sanaria
8:35 Vaccine Safety in Todays World and Perspectives
for the Future 3:30 Coffee Break
Neal Halsey, Director, Institute of Vaccine Safety,
Johns Hopkins University, School of Public 4:00 Roundtable on Conference Objectives
Health Closing Panel of Chairpersons with
Audience Participation
9:35 Pulic-Private Partnerships in Vaccine Research and
Development: Important Factors from a Vaccine Please visit our website at
Company Perspectives, and How a Public Partner http://www.gtcbio.com for update regarding our
Can Act to Support Company Involvement conferences. Registration forms can be
John Donnelly, Senior Director, Vaccine downloaded from our website.
Department, Chrion Corporation
For sponsorship and exhibition opportunities,
please call (626) 256-6405 or email to
10:05 Vaccines from R&D to Clinical Phase 2 and Field
sales@gtcbio.com.
Trials - A Private Startup Acquired by a Public
Biotech Company
George Lowell, CSO, ID Biomedical Other GTCBIO conferences:
Cancer Drug Research and Development
10:35 Coffee Break November 20-21, 2003, US Grant
San Diego, CA
11:05 Vaccine Development for Conventional Vaccines
from Phase I to Commercialization in a Startup Chemistry in Drug Discovery
Company March 25-26, 2004, San Diego, CA
Sharon Mates, Chairman and CEO, Functional Cytokines and Inflammation
Genetics, Inc., and Intra-Cellular Therapies, Inc. April 29-30, 2004, Princeton, NJ
Conference Registration Form Cancer Drug Research and Development
November 20-21, 2003, US Grant, San Diego
Register 3, the 4th goes FREE
Tony Hunter, Keynote Speaker, Professor, The Salk Institute.
Four Ways To Register: Protein phosphorylation and the new age of signal transduction
Mail: GTCBIO, 550 Fano St. Suite 303B, Monrovia, inhibitor drugs
CA 91016, U.S.A.
David Chaplin, Chief Executive Officer, Oxigene. Development of
Tel: (626) 256-6405
Combretastatin A4 as a Vascular Targeting Agent
Fax: (626) 256-6460
Online: http://www.gtcbio.com Jocelyn Holash, Associate Director, Regeneron. The VEGF-Trap:
A Novel and Potent VEGF Blocker With Wide-Ranging Therapeutic
Name ________________________Title _____________ and Investigational Potential
Steve Harrison, Director, Chiron. Novel CHK1 Inhibitors for
Dept. ________________ Company _________________ Chemosensitization
Helen Hua, Scientist, Celgene. TBA
Address: _______________________________________
Shanta Bantia, Director, BioCryst Pharmaceuticals. Purine
City __________________State __________Zip________ Nucleoside Phosphorylase Inhibitor - BCX-1777 in T-cell
Malignancies
Country ________________________________________ Oren Beske, Head of Cell Biology, Vitra Bioscciences, Inc. Using
the CellCard system to identify anti-proliferative compounds based
Phone _________________Email __________________ on both potency and cell-type selectivity
Registration Option (Please check one) Ben Tseng, Vice President, Maxim Pharmaceuticals. A Drug
Discovery Screen and Chemo-genetic Approach for Novel Apoptosis
Vaccines: from political, socio-economic, scientific, Inducers
provider, user and legal view points
by Aug 22 by Sep 22 by Oct 22 Sergey M. Kipriyanov, Head of Antibody Engineering, Affirmed
Commercial: $1196 $1345 $1,495 Therapeutics AG. Novel Recombinant Bispecific Molecules for
Academic/gov: $476 $535 $595 Immunotherapy of B Cell Tumors
Cancer Drug Research and Development Chaoyong Ma, Manager, Business Development, Phylonix. In
by Sep 20 by Oct 20 by Nov 20 Vivo Zebrafish Assays for Angiogenesis Drug Screening and Target
Commercial: $1,116 $1255 $1395 Validation
Academic/gov: $476 $535 $595
Sandra Chica, Medical Director, Perceptive Informatics, Inc.
Chemistry in Drug Discovery (2004)
Evaluation of the Effects of Anti-Angiogenic and Anti-Vascular
by Jan 25 by Feb 25 by Mar 25
Cancer Agents
Commercial: $1,116 $1255 $1395
Academic/gov: $476 $535 $595 Mark Rolfe, Sr. Director, Millennium Pharmaceuticals, Inc.
Cytokines and Inflammation (2004) Bortezomib, a Novel Proteasome Inhibitor for Cancer Therapy
by Feb 29 by Mar 29 by Apr 29 Karyl Schubert, Donald Danforth Plant Sciences Center. Use of
Commercial: $1,116 $1255 $1395 plants in cancer drug development
Academic/gov: $476 $535 $595
David W. Moskowitz, Chairman, CEO and CMO, GenoMed,
Payment method (Please check one) Inc. Towards Cancer Prevention: Clues from Genomic Epidemiology
Bill me, Check, Bank Transfer, Money Order Shay Soker, Assistant Professor of Surgery, Children's Hospital,
Visa, Master, Amex, Dinner Club, JCB Boston. Evaluation of Circulating Endothelial Cells as a Surrogate
Marker for Antiangiogenic Therapy of Cancer Patients
Card # ________________________________________
Guha Krishnaswamy, Professor, Chief, Division of Allergy and
Immunology, James H. Quillen V.A. Medical Center. Potential
Expiration Date _________________________________ Roles of Mast Cells in Cancer: Pharmacological Regulation
Cardholder Name ________________________________ Peter M. Fischer, Head, Discovery Research, Cyclacel Limited.
CDK Inhibitors as Anticancer Agents
Signature ______________________________________ Janice L Huff, Director, BioForce. Practical Nanoscale Assays for
Cancer Diagnostics
Cancellation: If you cancel eight weeks or more in advance of the conference you can
expect a full refund. Cancellation occurring four to eight weeks prior to the conference date Julian Woelcke, Head of Screening Operations Department,
receive a $200 refund or full voucher to another event. If you cancel less than four weeks
prior to the conference date, you can expect a full credit voucher to be used at another EVOTEC, OAI. Novel Biochemical Assay Formats to Screen for
GTCBIO event. You can change delegate name within the same company prior to the Inhibitors and Activators of p53
conference without any charge.
Note: all the speakers in this brochure have been confirmed to talk at this conference. Herbert A. Schmid, Norvartis. The New Somatostatin Analogue
Speakers and agenda subject to change without notice. In the event a speaker cancellation,
every effort to find a suitable replacement will be made.
SOM230 Is a Potent Inhibitor Of The GH/IGF-1 Axis
